Ceftaroline activity against Staphylococcus aureus isolated from patients with infective endocarditis, worldwide (2010-2019)

Helio S Sader; Cecilia G Carvalhaes; Rodrigo E Mendes

doi:10.1016/j.ijid.2020.11.130

Back

Ceftaroline activity against Staphylococcus aureus isolated from patients with infective endocarditis, worldwide (2010-2019)

Journal article

Peer reviewed

Ceftaroline activity against Staphylococcus aureus isolated from patients with infective endocarditis, worldwide (2010-2019)

Helio S Sader, Cecilia G Carvalhaes and Rodrigo E Mendes

International journal of infectious diseases, Vol.102, pp.524-528

01/2021

DOI: 10.1016/j.ijid.2020.11.130

PMID: 33207274

View Online

Abstract

To evaluate the antimicrobial activity of ceftaroline against Staphylococcus aureus isolated from patients with infective endocarditis (IE). 23,833 S. aureus isolates were collected consecutively from patients with bloodstream infections (BSI) from 2010 to 2019, via the SENTRY Antimicrobial Surveillance Program, including 396 isolates from patients with a diagnosis of IE. Isolates were collected from 340 medical centers worldwide and susceptibility tested by reference broth microdilution in a monitoring laboratory. The oxacillin resistance (MRSA) rate was 29.0% among IE isolates, and was higher in North America (40.3%) than in Europe (25.4%) or the Latin America/Asia-Pacific region (LATAM-APAC; 18.6%). Ceftaroline was active against 95.2% of IE isolates (MIC , 0.25/1 mg/L), with ceftaroline susceptibility higher in North America (99.2%) and LATAM-APAC (98.3%) than in Europe (92.0%). Among MRSA isolates from IE (n = 115; MIC , 1/2 mg/L), ceftaroline susceptibility was 98.0% in North America, 90.9% in LATAM-APAC, and 68.5% in Europe. Among BSI isolates, MRSA rates were 43.6% in North America and 25.6% in Europe, while ceftaroline susceptibility rates were 98.1% in North America and 95.4% in Europe. Ceftaroline demonstrated potent in vitro activity against a large collection of S. aureus isolates recovered from patients with BSI, including IE.

Anti-Bacterial Agents - pharmacology

Asia - epidemiology

Bacteremia - epidemiology

Bacteremia - microbiology

Cephalosporins - pharmacology

Endocarditis, Bacterial - microbiology

Epidemiological Monitoring

Europe - epidemiology

Humans

Latin America - epidemiology

Methicillin-Resistant Staphylococcus aureus - drug effects

Methicillin-Resistant Staphylococcus aureus - isolation & purification

North America - epidemiology

Staphylococcal Infections - epidemiology

Staphylococcal Infections - microbiology

Staphylococcus aureus - drug effects

Staphylococcus aureus - isolation & purification

Details

Title: Subtitle: Ceftaroline activity against Staphylococcus aureus isolated from patients with infective endocarditis, worldwide (2010-2019)
Creators: Helio S Sader - JMI Laboratories
Cecilia G Carvalhaes - JMI Laboratories
Rodrigo E Mendes - JMI Laboratories
Resource Type: Journal article
Publication Details: International journal of infectious diseases, Vol.102, pp.524-528
DOI: 10.1016/j.ijid.2020.11.130
PMID: 33207274
NLM abbreviation: Int J Infect Dis
ISSN: 1201-9712
eISSN: 1878-3511
Grant note: DOI: 10.13039/100007819, name: Allergan
Language: English
Date published: 01/2021
Academic Unit: Pathology
Record Identifier: 9984185166802771

Metrics

29 Record Views

11 Times Cited - Web of Science

See more details